Sickle Cell Hemoglobinopathies and Bone Health

• ClinicalTrials.gov Identifier: NCT02306993
• Recruitment Status: Active, not recruiting
• First Posted: December 3, 2014
• Last Update Posted: November 3, 2022
• Sponsor: UConn Health
• Information provided by (Responsible Party): Biree Andemariam, UConn Health

Tracking Information

• First Submitted Date: December 1, 2014
• First Posted Date: December 3, 2014
• Last Update Posted Date: November 3, 2022
• Actual Study Start Date: May 2014
• Estimated Primary Completion Date: December 2025 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: December 1, 2014)

Hemoglobin genotype with serum bone turnover markers and bone density [ Time Frame: 3 years ]

Assess the association of hemoglobin genotype with serum bone turnover markers and bone density.

• Original Primary Outcome Measures: Same as current
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Sickle Cell Hemoglobinopathies and Bone Health
• Official Title: Sickle Cell Hemoglobinopathies and Bone Heath
• Brief Summary: This research study has two purposes. The first purpose is to determine whether having sickle cell trait (SCT) is a risk factor for the development of bone thinning at an earlier age than expected. Nearly 10% of African Americans (AA) carry sickle cell trait and most of them are unaware of it. African Americans are less likely to develop thin bones than whites, but if they sustain a bone fracture, they are more likely to die from it. We believe having sickle cell trait may lead to bone thinning and predispose a subset of African Americans to dangerously thin bones. The second purpose is to try to understand why individuals with sickle cell disease (SCD) have thinner bones than healthy individuals do. Doctors have already discovered that people with sickle cell disease have very thin bones, but they have not determined why. Our study will try to identify whether the bone thinning is from the body not making enough bone or from the body losing bone once it is made.
• Detailed Description: SCD is a hereditary disease arising only when two parents carrying sickle cell trait (SCT) conceive a child. SCT is clinically silent but very common in African Americans with a ~10% prevalence, although most carriers are unaware of their status. There are no data on bone mineral density (BMD) or vitamin D status in these individuals. Although it is clear that those with SCD have accelerated bone thinning the effect of SCT on bone metabolism or fractures has not been studied. Although the incidence of hip fracture in AA women is about half that of white women, the etiology and risk factors of fractures in AA women are not clearly defined, and it is intriguing to postulate that SCT may have a relationship to bone metabolism and fracture risk in this population, and thus contribute to racial disparity. We hypothesize that the mechanisms underlying altered bone homeostasis in SCD are different than in the general population but perhaps similar to those with SCT. We also hypothesize that SCT is a state of reduced bone mineralization which may contribute to racially disparate outcomes among AAs with bone fractures. Our objectives are (1) to define the mechanisms of bone loss in SCD and (2) to evaluate parameters of bone metabolism in human subjects with SCT compared to those with normal hemoglobin and those with SCD. We will investigate the effect of SCD and SCT on bone homeostasis in premenopausal AA subjects via serum bone turnover markers, calciotrophic hormones and bone mineral density (BMD) testing. We hypothesize that premenopausal AA women with SCT will have significantly lower BMD and higher serum bone turnover markers than race- and age-matched control AA women. In addition, we will explore Vitamin D status and its relationship to bone turnover and BMD in all three groups. We further postulate that bone homeostasis in SCT subjects will be intermediate between healthy controls and subjects with SCD.
• Study Type: Observational
• Study Design: Observational Model: Case-Control; Time Perspective: Prospective
• Target Follow-Up Duration: Not Provided

Biospecimen

Retention:   Samples Without DNA

Description:

Blood will be collected once from each subject by certified study staff at UCHC, CCMC or the participating approved community sites in a private setting.Subjects will donate ~12-15 cc of whole blood via venipuncture. Blood will be collected into 3 vacutainer tubes: one 3.5-mL lavender top tube for CBC and hemoglobin electrophoresis, one 3.5-mL yellow top tube for serum calcium and phosphate, and one 5-mL red-top tube for 25-OH vitamin D, P1NP, CTX, and PTH analysis. The

• Sampling Method: Non-Probability Sample
• Study Population: The target population includes healthy African American female volunteers with and without SCT and African American female volunteers with SCD.

Condition

• Sickle Cell Disease
• Sickle Cell Trait

Intervention

• Other: Healthy volunteers without SCT
  Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
• Other: Healthy volunteers with SCT
  Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
• Other: Volunteers with SCD
  Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.

Study Groups/Cohorts

• Healthy volunteers without SCT
  Includes Healthy African American female volunteer between the ages of 18 and 45 years without sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
  Intervention: Other: Healthy volunteers without SCT
• Healthy volunteers with SCT
  Includes Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
  Intervention: Other: Healthy volunteers with SCT
• Volunteers with SCD
  Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell disease. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell disease affects bone.
  Intervention: Other: Volunteers with SCD

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Estimated Enrollment (submitted: December 1, 2014): 45
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: December 2025
• Estimated Primary Completion Date: December 2025 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Age 18-45 years.
• Female.
• Regular menstrual periods.
• Self-identification of African American race.

Exclusion Criteria:

• Taking oral contraceptives or medications known to influence bone metabolism (e.g. Glucocorticoids, anti-resorptive or anabolic medications for osteoporosis, pharmacologic Vit D dosing).
• Known metabolic bone disorder (e.g. uncontrolled thyroid disease, hyperparathyroidism).
• Pregnant, breast-feeding, or within 3 months post-partum.
• Taking an investigational drug.

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 18 Years to 45 Years (Adult)
• Accepts Healthy Volunteers: Yes
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02306993
• Other Study ID Numbers: 14-136-6
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Biree Andemariam, UConn Health
• Original Responsible Party: Same as current
• Current Study Sponsor: UConn Health
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Biree Andemariam, M.D; UConn Health

• PRS Account: UConn Health
• Verification Date: November 2022